Dr. Schuster shares results from the global JULIET trial of the CAR T-cell therapy tisagenlecleucel in patients with relapsed/refractory diffuse large B-cell lymphoma – a patient population with the “greatest unmet need.”
Recent Articles
Head-to-Head Trial Confirms Acalabrutinib’s Noninferiority to Ibrutinib in CLL
At EHA2021 Virtual, the annual congress of the European Hematology Association, researchers presented results from the first head-to-head trial of Bruton tyrosine kinase (BTK)...
B-Cell Depletion Linked to Prolonged COVID-19 in Lymphoma
A study of patients with B-cell non-Hodgkin lymphoma hospitalized for COVID-19 has found that these patients had a higher incidence of prolonged evolution of...
PDE9 Inhibitor Shows Promise as Monotherapy and With Hydroxyurea in Sickle Cell Disease
Data from two new studies indicated that daily dosing of the oral phosphodiesterase type 9 (PDE9) inhibitor IMR-687, at doses up to 200 mg,...
JAMA Editor-in-Chief Resigns After Releasing Content Questioning Racism in Medicine
In late June, Howard Bauchner, MD, will resign from his role as editor-in-chief of the Journal of the American Medical Association (JAMA) following a...
Will DIY Testing Outlive the COVID-19 Pandemic?
The COVID-19 pandemic has revolutionized diagnostic testing. As the pandemic eases and related restrictions are lifted, public health officials and scientists are looking to...
Current Issue
June 2021 Volume 7 Issue 7
This issue reviews the management and prevention of peripheral neuropathy, early successes of SCD screening programs in sub-Saharan Africa, and more.